The role of aldosterone in resistant hypertension: Implications for pathogenesis and therapy

Current Hypertension Reports

Volumn 9, Issue 2, 2007, Pages 98-105

  Epstein, Murray ^a   Calhoun, David A ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; METHYLDOPA; MINOXIDIL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; VERAPAMIL;

ADD ON THERAPY; ALBUMINURIA; ALDOSTERONE RELEASE; ANTIHYPERTENSIVE ACTIVITY; BREAST TENDERNESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FLUID RETENTION; GYNECOMASTIA; HAIR GROWTH; HORMONE SYNTHESIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERVOLEMIA; HYPOKALEMIA; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REVIEW; RISK FACTOR; SIDE EFFECT; SODIUM RETENTION; UNSPECIFIED SIDE EFFECT;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; SEVERITY OF ILLNESS INDEX;

EID: 34249113478     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0018-2     Document Type: Review

References (53)

1. Foster RH, MacFarlane CH, Bustamante MO: Recent progress in understanding aldosterone secretion. Gen Pharmacol 1997, 28:647-651.
2. Fuller PJ: Aldosterone's effects and mechanism of action. Curr Opin Endocrinol Diabetes 1997, 4:218-224.
3. Luetscher JA Jr, Neher JP, Wettstein A: Isolation of crystalline aldosterone from the urine of a nephrotic patient. Experientia 1954, 10:456-458.
4. Edelman IS, Fimognari GM: On the biochemical mechanism of action of aldosterone. Recent Prog Horm Res 1968, 24:1-44.
5. Rossier BC: Mechanisms of action of mineralocorticoid hormones. Endocr Res 1989, 15:206-226.
6. Duprez D, De Buyzere M, Rietzchel ER, Clement DL: Aldosterone and vascular damage. Curr Hypertens Rep 2000, 2:327-334.
7. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
8. Rocha R, Chander PN, Zuckerman A, et al.: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232-237.
9. Epstein M: Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertension 2001, 19:829-842.
10. Wehling M: Non-genomic actions of steroid hormones. Trends Endocrinol Metab 1994, 5:347-353.
11. Wehling M, Spes CH, Win N, et al.: Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998, 83:3517-3522.
12. Christ M, Douwes K, Eisen C, et al.: Rapid non-genomic effects of aldosterone on sodium transport in rat vascular smooth muscle cells: involvement of the Na+/H+ antiport. Hypertension 1995, 25:117-123.
13. Wehling M, Neylon CB, Fullerton M, et al.: Non-genomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995, 76:973-979.
14. Wehling M: Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med 1995, 73:439-447.
15. Ebata S, Muto S, Okada K, et al.: Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by non-genomic and genomic mechanisms. Kidney Int 1999, 56:1400-1412.
16. Bonvalet JP, Alfaidy N, Farman N, et al.: Aldosterone: intracellular receptors in human heart. Eur Heart J 1995, 16(Suppl N):92-97.
17. Kornel L: Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994, 7:100-103.
18. Lombes M, Oblin ME, Gasc JM, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503-510.
19. Young M, Fullerton M, Dilley R, et al.: Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
20. Rocha R, Funder JW: The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002, 970:89-100.
21. Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000, 141:3871-3878.
22. Pitt B, Remme W, Zannad F, et al., for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
23. Lacolley P, Labat C, Pujol A, et al.: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats. Circulation. 2002, 106:2848-2853.
24. Veglio F, Molino P, Cat Genova G, et al.: Impaired baroreflex function and arterial compliance in primary aldosteronism. J Hum Hypertens 1999, 13:29-36.
25. Epstein M: Role of aldosterone blockade in the management of hypertension and cardiovascular disease. In Kidney and Blood Pressure Regulation. Edited by Suzuki H, Saruta T. Basel: Karger; 2004:90-104 [Contributions to Nephrology; vol 143.]
26. Epstein M, Williams GH, Weinberger M, et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
27. Black HR, Elliott WJ, Grandits G, et al., for the CONVINCE Research Group: Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
28. Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393-404.
29. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1999, 350:757-764.
30. Gomez-Sanchez CE, Zhou MY, Cozza EN, et al.: Aldosterone biosynthesis in the rat brain. Endocrinology 1997, 138:3369-3373.
31. Nishizaka MK, Zaman MA, Green SA, et al.: Impaired endothelial-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857-2861.
32. Epstein M: Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119:912-919.
33. Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
34. Mosso L, Carvajal C, Gonzalez A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161-165.
35. Calhoun DA, Nishizaka MK, Zaman MA, et al.: High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
36. Gallay BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
37. Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
38. Štrauch B, Zelinka T, Hampf M, et al.: Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003, 17:349-352.
39. Taler S, Textor SC, Augustine JE: Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002, 39:982-988.
40. Blasé HL, Panagopoulos G, Michelis MF: Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renal profiling. Am J Hypertens 2003, 16:187-193.
41. Garg JJP, Elliott WJ, Folker A, et al., for the RUSH Hypertension Service: Resistant hypertension revisited: a comparison of 2 university-based cohorts. Am J Hypertens 2005, 18:619-626.
42. Ernst ME, Carter BL, Goerdt CJ, et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:353-358.
43. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264.
44. The Multiple Risk Intervention Trial Research Group (MRFIT): Mortality rates after 10-1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990, 82:1616-1628.
45. Materson BJ, Reda DJ, Cushman WC, et al., for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Results of combination antihypertensive therapy after failure of each of the components. J Hum Hypertens 1995, 9:791-796.
46. Ramsay LE, Silas JH, Freestone S: Diuretic treatment of resistant hypertension. BMJ 1980, 281:1101-1103.
47. Ouzan J, Pérault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333-339.
48. Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
49. Mahmud A, Mahgoub M, Hall M, et al.: Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagononist spironolactone? Am J Hypertens 2005, 18:1631-1635.
50. Saha C, Eckert GJ, Ambrosius WT, et al.: Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481-487.
51. Sharabi Y, Adler E, Shamis A, et al.: Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006, 19:750-755.
52. Weinberger MH, Roniker B, Krause SL, et al.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-716.
53. Weinberger MH, White WB, Ruilope L-M, et al.: Effects of eplerenone versus losartan inpatients with low-renin hypertension. Am Heart J 2005, 150:426-433.